Validation of GenProb ‐ T1D and its clinical utility for differentiating types of diabetes in a biobank from a US healthcare system
Journal of Diabetes Investigation · 2025
DOI: 10.1111/jdi.14297 ↗Kurz gefasst
Validierungsstudie in der Zeitschrift Journal of Diabetes Investigation, 2025. Verfasst von Liana K Billings und 10 weiteren Autor:innen. Beteiligte Einrichtung: Endeavor Health, Evanston, IL, USA. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Biological Specimen Banks. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Themen: Diabetes mellitus
Abstract (Originalsprache)
Atypical diabetes with overlapping clinical features of type 1 (T1D) and type 2 (T2D) is common and challenging diagnostically and for implementing effective treatment. Here, we validate a recently reported genetic probability of type 1 diabetes (GenProb‐T1D) from the UK Biobank (UKB) for differentiating type 1 diabetes and type 2 diabetes in a diabetes patient cohort from a healthcare system‐based biobank in the USA. Among 3,363 diabetes patients, we confirmed the performance of GenProb‐T1D in differentiating typical type 1 diabetes vs type 2 diabetes. Furthermore, for 359 atypical diabetes patients, those with GenProb‐T1D higher than the pre‐defined cutoff derived from the UKB had clinical presentations more consistent with that of typical type 1 diabetes. Similar findings were found in participants of European and non‐European ancestries. This study provides necessary validation to translate GenProb‐T1D into genetic testing in a multi‐ancestry cohort. Measuring underlying genetic susceptibility of type 1 diabetes and type 2 diabetes can supplement current clinical tools for earlier and more accurate diagnoses of diabetes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Endeavor Health, Evanston, IL, USA.
- University of Chicago Pritzker School of Medicine, Chicago, IL, USA.
ORCID-Profile: Jianfeng Xu
Zitieren
APA
Billings, L. K., Shi, Z., Mulford, A. J., Wei, J., Tran, H., Ashworth, A., Zheng, S. L., Dunnenberger, H. M., Hulick, P. J., Sanders, A. R., & Xu, J. (2025). Validation of GenProb ‐ T1D and its clinical utility for differentiating types of diabetes in a biobank from a US healthcare system. Journal of Diabetes Investigation. https://doi.org/10.1111/jdi.14297
Vancouver
Billings LK, Shi Z, Mulford AJ, Wei J, Tran H, Ashworth A, et al. Validation of GenProb ‐ T1D and its clinical utility for differentiating types of diabetes in a biobank from a US healthcare system. Journal of Diabetes Investigation. 2025. doi:10.1111/jdi.14297
BibTeX
@article{Billings2025,
author = {Billings, Liana K and Shi, Zhuqing and Mulford, Ashley J and Wei, Jun and Tran, Huy and Ashworth, Annabelle and Zheng, S Lilly and Dunnenberger, Henry M and Hulick, Peter J and Sanders, Alan R and Xu, Jianfeng},
title = {Validation of GenProb ‐ T1D and its clinical utility for differentiating types of diabetes in a biobank from a US healthcare system},
journal = {Journal of Diabetes Investigation},
year = {2025},
doi = {10.1111/jdi.14297}
}
EUVIMED